Abstract | BACKGROUND: OBJECTIVE: To review rifaximin for treatment of IBS and SIBO. METHODS: RESULTS/CONCLUSION:
Rifaximin improved global symptoms in 33 - 92% of patients and eradicated SIBO in up to 84% of patients with IBS, with results sustained up to 10 weeks post-treatment. Rifaximin caused a lower number of adverse events compared with metronidazole or levofloxacin and may have a more favorable adverse event profile than systemic antibiotics, without clinically relevant antibiotic resistance.
|
Authors | Mark Pimentel |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 18
Issue 3
Pg. 349-58
(Mar 2009)
ISSN: 1744-7658 [Electronic] England |
PMID | 19243285
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Animals
- Clinical Trials as Topic
- Drug Tolerance
- Humans
- Intestinal Diseases
(diagnosis, drug therapy, microbiology)
- Microbial Viability
(drug effects)
- Rifamycins
(chemistry, metabolism, pharmacology, therapeutic use)
- Rifaximin
|